Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a focus on microRNAs and their role in diseases. Co.'s product candidates include: cobomarsen, which is for the treatment of patients with certain cancers that have elevated microRNA-155, including cutaneous T-cell lymphoma, and adult T-cell leukemia/lymphoma; remlarsen, which is for the potential treatment of patients with pathological fibrosis, including idiopathic pulmonary fibrosis; and MRG-110, which is for the treatment of heart failure, wound healing, and other ischemic disease. The MGEN average annual return since 2014 is shown above.
The Average Annual Return on the MGEN average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MGEN average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MGEN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
